Literature DB >> 17935139

Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.

Donatella Aldinucci1, Debora Lorenzon, Lara Cattaruzza, Antonio Pinto, Annunziata Gloghini, Antonino Carbone, Alfonso Colombatti.   

Abstract

The expression of CCL5/Rantes by Hodgkin (H) and Reed-Sternberg (RS) cells has been recently documented. In the present study we demonstrated that the CCL5 receptor (CCR5) is constitutively expressed by Hodgkin Lymphoma (HL)-derived cell lines (i.e. L-428, KM-H2, L-1236 and L-540) as shown by immunohistochemistry, flow cytometry and western blotting and also detected by immunohistochemistry on primary H-RS cells from lymph node tissues. sCD40L never significantly affected CCR5 expression, whereas a short exposure to doxorubicin down regulated its expression. CCR5 receptors on HL cell lines were functionally active, since neutralizing anti-CCL5 monoclonal antibodies inhibited basal proliferation of HL-derived cell lines and recombinant CCR5 ligands (CCL3/Mip-1 alpha, CCL4/Mip1 beta and CCL5/Rantes) increased their clonogenic growth. CCL5 secretion by L-1236, L-428 and KM-H2 cells was stimulated by CD40 engagement and also by coculturing L-1236 cells on primary stromal fibroblasts from HL-involved lymph nodes (HLF). Coculture experiments indicated that a direct contact of H-RS cells induces HLF cells to produce CCL5. Supernatants from L-1236, L-428 and KM-H2 cells stimulated migration of purified CD4+ T-cells and eosinophils in vitro. The migratory response to HL-cell lines supernatants was only partially neutralized (CD4+ cells: 70%; esinophils: 36%) by anti-CCL5 antibodies, reinforcing the notion that multiple chemokines are involved in the recruitment of nonmalignant reactive cells in HL tissues. Taken together, our results indicate a possible involvement of the CCR5/CCR5-ligands signaling in the regulation of H-RS cells growth and in the formation/maintenance of the typical tissue microenvironment of HL. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17935139     DOI: 10.1002/ijc.23119

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma.

Authors:  Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Association of chemokine CCL5 and systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  J Hum Genet       Date:  2008-03-27       Impact factor: 3.172

3.  WNT5A: a motility-promoting factor in Hodgkin lymphoma.

Authors:  F Linke; S Zaunig; M M Nietert; F von Bonin; S Lutz; C Dullin; P Janovská; T Beissbarth; F Alves; W Klapper; V Bryja; T Pukrop; L Trümper; J Wilting; D Kube
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

4.  Role of RANTES and its receptor in gastric cancer metastasis.

Authors:  Zhixin Cao; Xiangshang Xu; Xuelai Luo; Li Li; Bin Huang; Xiaolan Li; Deding Tao; Junbo Hu; Jianping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

5.  Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.

Authors:  Sensen Lin; Shuying Wan; Li Sun; Jialiang Hu; Dongdong Fang; Renping Zhao; Shengtao Yuan; Luyong Zhang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

6.  Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5).

Authors:  A Steen; A H Sparre-Ulrich; S Thiele; D Guo; T M Frimurer; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 7.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 8.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 9.  New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.

Authors:  Catherine Diefenbach; Christian Steidl
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 10.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.